Sunday 18 October 2026
Export SPRB’s income statement to Excel — free account
Spruce Biosciences, Inc.
SPRB Healthcare Biotechnology
Spruce Biosciences, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $4.9 million, down 51.3% from fiscal 2023. In the quarter to June 2026, revenue fell 75.9%, EPS fell 90.9%, free cash flow fell 152.1% and total debt rose 427.2%, each against the same quarter a year earlier.
39.65
1.82
−4.39%
Follow SPRB
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (105.98%) | (148.85%) | (109.24%) | (167.93%) |
+8 more TTM periods Free account |
|
| (82.38%) | (84.70%) | (79.34%) | (119.08%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(56.94%) | (85.99%) | (92.72%) | (940.83%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(17.60) | (21.39) | (43.45) | (84.45) | |
Free Cash Flow |
(42.78) | (29.35) | (33.33) | (47.55) | |
Capital Expenditures |
(0.15) | (0.02) | — | — | |
| Other line items | |||||
Cash ROIC |
(22.86%) | (30.83%) | (36.45%) | (286.54%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(26.63) | (46.71) | (405.70) | (353.48) | |
Operating CF/Net income |
0.83 | 0.79 | 0.86 | 0.99 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
(0.17) | (0.06) | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(17.53) | (21.38) | (43.45) | (84.45) | |
Capex per Share |
(0.06) | (0.01) | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | — | — |
Columns are period end dates